Amgen Inc. (AMGN) vs Bristol Myers Squibb Company (BMY)
- Amgen Inc. AMGN 432.49 −0.35%
- Bristol Myers Squibb Company BMY 59.71 −1.42%
Amgen Inc. and Bristol Myers Squibb Company are both Drug Manufacturers General companies. Amgen Inc. is the larger, with a market value of $234.7B against $123.7B — 1.9× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.2× against 26.7×. Amgen Inc. grew revenue faster over the last twelve months: 9.10% against 3.11%. Amgen Inc. has the higher net margin (23.0% vs 18.9%) and the lower return on invested capital (13.0% vs 13.7%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.22% vs 2.30%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Amgen Inc. on 7.
Valuation
Profitability
| Metric | AMGN | BMY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.52% | 70.16% | 72.77% |
| Operating margin | 29.99% | 24.22% | 18.77% |
| Net margin | 22.95% | 18.87% | 8.27% |
| Free cash flow margin | 26.71% | 23.26% | 17.18% |
| Return on equity | 91.47% | 46.63% | 5.87% |
| Return on assets | 9.53% | 10.18% | 2.57% |
| Return on invested capital | 12.98% | 13.69% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack